Direct dopamine agonists like the anti-Parkinsons drug pramipexole are known aphrodisiacs different from ED drugs like PDE inhibitors. Prami is actually the only drug specifically approved by the US FDA to treat lack of sexual libido ie lack of psychological sexual arousal. Incidentally, it also has the rather embarrassing side-effect of making 80 years old Parkinsons disease patients compulsively masturbating publicly in retirement homes while talking dirty.:D Or turning old ladies who never gamble in their entire life into compuslive gamblers, sometime gambling away the family house and retirement savings.. Rather strange side-effects of DA agonism!! (google Parkinsons hypersexuality gambling ) or check this out:
Note that the effect is not the same as that of ED drugs which target the physical erection aspect. It is the the mental aspect, the arousal phase of sexual behavior originating from the brain. Rats on prami have an increase in humping and jerking off (pardon the term) of at least 200% compared to their sober littermate control [ref].
Now my question is: Can a selective Dopamine Reuptake Inhibitor (or releaser) have the same effect as direct DA agonists in inducing sexual arousal ? The reason beiing that selective DRIs may not have the other effects of direct DA agonists such as pucking or turning into a big time gambler.. Obviously, it is well known that non-selective SNDRI inhibitors like cocaine have sexual arousing aphrodisiac effects. But with cocaine and related SDRIs, the Serotonergic activity has the paradoxical effect of blocking the sexual arousal effect induced by DA uptake blockade. Kind of like a sexual arousal push-pull between DA push and SERT pull. This is not unexpected since SSRIs are notorious in inducing psychological sexual dysfunction.
So the question is: would selective DRIs (DRAs) or at least selective DNRI/A have the sexual arousal effect of D2 agonists but without the sexual arousal blocking serotonergic and the emesis (vomiting) inducing effect of direct D2 agonists?
ps: come to think of it, note that unlike Serotonin and NE, so far in the literature no selective DA releaser DRA has been described afaik .. wonder what kind of pharmacological effect a Selective Dopamine Releaser would have? not a Reuptake inhibitor but a Dopamine Releaser
Warn families of risk of sex and gambling addictions with Parkinson's drugs, doctors told The families of Parkinson's sufferers must be warned about dangers of sex and gambling addictions caused by drugs used to treat the disease, doctors have been told.
New NHS guidelines, due to be released next month, include impulse control disorders for the first time, stating that health professionals should discuss the potential for dramatic change in behaviour with the "family and carers" as well as the patient....
Note that the effect is not the same as that of ED drugs which target the physical erection aspect. It is the the mental aspect, the arousal phase of sexual behavior originating from the brain. Rats on prami have an increase in humping and jerking off (pardon the term) of at least 200% compared to their sober littermate control [ref].
Now my question is: Can a selective Dopamine Reuptake Inhibitor (or releaser) have the same effect as direct DA agonists in inducing sexual arousal ? The reason beiing that selective DRIs may not have the other effects of direct DA agonists such as pucking or turning into a big time gambler.. Obviously, it is well known that non-selective SNDRI inhibitors like cocaine have sexual arousing aphrodisiac effects. But with cocaine and related SDRIs, the Serotonergic activity has the paradoxical effect of blocking the sexual arousal effect induced by DA uptake blockade. Kind of like a sexual arousal push-pull between DA push and SERT pull. This is not unexpected since SSRIs are notorious in inducing psychological sexual dysfunction.
So the question is: would selective DRIs (DRAs) or at least selective DNRI/A have the sexual arousal effect of D2 agonists but without the sexual arousal blocking serotonergic and the emesis (vomiting) inducing effect of direct D2 agonists?
ps: come to think of it, note that unlike Serotonin and NE, so far in the literature no selective DA releaser DRA has been described afaik .. wonder what kind of pharmacological effect a Selective Dopamine Releaser would have? not a Reuptake inhibitor but a Dopamine Releaser
Last edited: